Amplified Centrosomes in Breast Cancer: A Potential Indicator of Tumor Aggressiveness

[1]  Carol Reynolds,et al.  Centrosome amplification drives chromosomal instability in breast tumor development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Ullrich,et al.  Molecular targets for breast cancer therapy and prevention , 2001, Nature Medicine.

[3]  L. Loeb,et al.  A mutator phenotype in cancer. , 2001, Cancer research.

[4]  Y. A. Minamishima,et al.  Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. , 2001, Cancer genetics and cytogenetics.

[5]  K. Münger,et al.  Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. , 2001, Cancer research.

[6]  L. Liotta,et al.  Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. , 2001, Cancer research.

[7]  A. Khodjakov,et al.  Requirement of a Centrosomal Activity for Cell Cycle Progression Through G1 into S Phase , 2001, Science.

[8]  Kristen L Murphy,et al.  A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53‐null mammary epithelial cell mode. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  D J O'Kane,et al.  A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. , 2000, The Journal of urology.

[10]  Y. Chiew,et al.  Expression of c‐erbB receptors, heregulin and oestrogen receptor in human breast cell lines , 2000, International journal of cancer.

[11]  R. Jenkins,et al.  The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. , 2000, The Journal of molecular diagnostics : JMD.

[12]  J. Slingerland,et al.  Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Mcshea,et al.  Identification of CIP-1-associated Regulator of Cyclin B (CARB), a Novel p21-binding Protein Acting in the G2 Phase of the Cell Cycle* , 2000, The Journal of Biological Chemistry.

[14]  J. Russo,et al.  Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer , 2000 .

[15]  Patrick E Carroll,et al.  Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression , 2000, Oncogene.

[16]  E. Schröck,et al.  Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations , 2000, Genes, chromosomes & cancer.

[17]  W. Lingle,et al.  Altered centrosome structure is associated with abnormal mitoses in human breast tumors. , 1999, The American journal of pathology.

[18]  A. Ashworth,et al.  Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification , 1999, Current Biology.

[19]  William F. Morgan,et al.  Genomic instability in Gadd45a-deficient mice , 1999, Nature Genetics.

[20]  W. Lingle,et al.  Microtubule Nucleating Capacity of Centrosomes in Tissue Sections , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[21]  Jiri Bartek,et al.  Centrosome duplication in mammalian somatic cells requires E2F and Cdk2–Cyclin A , 1999, Nature Cell Biology.

[22]  Patrick E Carroll,et al.  Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.

[23]  T. Stearns,et al.  Cyclin-dependent kinase control of centrosome duplication. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[25]  S. Braun,et al.  p21cip-1/waf-1 Deficiency Causes Deformed Nuclear Architecture, Centriole Overduplication, Polyploidy, and Relaxed Microtubule Damage Checkpoints in Human Hematopoietic Cells , 1999 .

[26]  J. Maller,et al.  Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. , 1999, Science.

[27]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[28]  D. Roop,et al.  Analysis of centrosome abnormalities and angiogenesis in epidermal‐targeted p53172H mutant and p53‐knockout mice after chemical carcinogenesis: Evidence for a gain of function , 1998, Molecular carcinogenesis.

[29]  R. White,et al.  BRCA1 is associated with the centrosome during mitosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[31]  H Knecht,et al.  Centrosome defects and genetic instability in malignant tumors. , 1998, Cancer research.

[32]  J. Ingle,et al.  Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S N Thibodeau,et al.  Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. , 1998, Nucleic acids research.

[34]  M. Meguid,et al.  Estrogen receptor expression in benign breast epithelium and breast cancer risk. , 1998, Journal of the National Cancer Institute.

[35]  L. Hartmann,et al.  Chromosome-specific aneusomy in carcinoma of the breast. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Woude,et al.  Abnormal Centrosome Amplification in the Absence of p53 , 1996, Science.

[37]  S. Bates,et al.  Normal p53 status and function despite the development of drug resistance in human breast cancer cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[38]  D. Conte,et al.  Deregulation of cyclin E in breast cancer. , 1995, Oncogene.

[39]  Teri Oldaker,et al.  DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients , 1993, Breast Cancer Research and Treatment.

[40]  R. Camplejohn,et al.  DNA index, S-phase fraction, histological grade and prognosis in breast cancer. , 1990, British Journal of Cancer.

[41]  G. Greene,et al.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.

[42]  M. Radu,et al.  Establishment and characterization of a cell line of human breast carcinoma origin. , 1979, European journal of cancer.

[43]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[44]  J. Price.  Metastasis from human breast cancer cell lines , 2005, Breast Cancer Research and Treatment.

[45]  W. Lingle,et al.  Methods for the analysis of centrosome reproduction in cancer cells. , 2001, Methods in cell biology.

[46]  B. Brinkley,et al.  Managing the centrosome numbers game: from chaos to stability in cancer cell division. , 2001, Trends in cell biology.

[47]  J. Russo,et al.  Developmental, cellular, and molecular basis of human breast cancer. , 2000, Journal of the National Cancer Institute. Monographs.

[48]  S. Braun,et al.  p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. , 1999, Blood.

[49]  J. B. Rattner,et al.  The relationship of HsEg5 and the actin cytoskeleton to centrosome separation. , 1996, Cell motility and the cytoskeleton.

[50]  R. Gelber,et al.  Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  L. Kwak,et al.  The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Diana Anderson.  In Vitro Models , 1990, Drug safety.